Highly selective angiotensin II (Ang II) type 1 (AT1) receptor blockers (ARBs) are now available. The AT1 receptor is a member of the G protein-coupled receptor (GPCR) superfamily and block the diverse effects of Ang II. Several ARBs are available for clinical use. Most ARBs have common molecular structures (biphenyl-tetrazol and imidazole groups) and it is clear that ARBs have ‘class effects’. On the other hand, recent clinical studies have demonstrated that not all ARBs have the same effects, and some benefits conferred by ARBs may not be class effects, and instead may be ‘molecular effects’. In addition, each ARB has been clearly shown to have specific molecular effects in basic experimental studies, and these effects may be due to small differences in the molecular structure of each ARB. However, it is controversial whether ARBs have molecular effects in a clinical setting. Although the presence of molecular effects for each ARB based on experimental studies may not directly influence the clinical outcome, this possibility has not been adequately evaluated. This review focuses on the class effects versus molecular effects of ARBs from bench to bedside.
de Gasparo M. , Catt KJ, Inagami T., et al. International Union of Pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev2000; 52: 415-472.
2.
Miura S., Fujino M., and Saku K.Angiotensin II receptor blocker as an inverse agonist: a current perspective . Curr Hypertens Rev2005; 1: 115-121.
3.
Noda K., Saad Y., Kinoshita A., et al. Tetrazole and carboxylate groups of angiotensin receptor antagonists bind to the same subsite by different mechanisms. J Biol Chem1995; 270: 2284-2289.
4.
Feng YH, Noda K., Saad Y., et al. The docking of Arg2 of angiotensin II with Asp281 of AT1 receptor is essential for full agonism. J Biol Chem1995; 270: 12846-12850.
5.
Noda K., Saad Y., Karnik SS, et al. Interaction of Phe8 of angiotensin II with Lys199 and His256 of AT1 receptor in agonist activation. J Biol Chem1995; 270: 28511-28514.
6.
Feng, YH, Miura S., Husain A., et al. Mechanism of constitutive activation of the AT1 receptor: influence of the size of the agonist switch binding residue Asn(111). Biochemistry1998; 37: 15791-15798.
7.
Miura S., Feng YH, Husain A., et al. Role of aromaticity of agonist switches of angiotensin II in the activation of the AT1 receptor. J Biol Chem1999; 274: 7103-7110.
8.
Timmermans PB , Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev1993 ; 45: 205-251.
9.
Tuccinardi T. , Calderone V., Rapposelli S., and Martinelli A.Proposal of a new binding orientation for non-peptide AT1 antagonists: homology modeling, docking and three-dimensional quantitative structure-activity relationship analysis. J Med Chem2006; 49: 4305-4316.
10.
Fabia MJ, Abdilla N., Oltra R., Fernandez C., and Redon J.Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens2007; 25: 1327-1336.
11.
Oparil S., Williams D., Chrysant SG, Marbury TC, and Neutel J.Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens2001; 3: 283-291, 318.
12.
Kivlighn SD , Zingaro GJ, Gabel RA, et al. In vivo pharmacology of an angiotensin AT1 receptor antagonist with balanced affinity for AT2 receptors. Eur J Pharmacol1995; 294: 439-450.
13.
Zhang J., Pfaffendorf M., Zhang JS, and Van Zwieten PAA non-competitive type of angiotensin-receptor antagonism by losartan in renal artery preparations. Eur J Pharmaco. 1994; 252: 337-340.
14.
Shibouta Y. , Inada Y., Ojima M., et al. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2’-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2’-(1H-tetrazol-5- yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116). J Pharmacol Exp Ther1993; 266: 114-120.
15.
Le MT, Pugsley MK, Vauquelin G., and Van Liefde I.Molecular characterization of the interactions between olmesartan medoxomil and telmisartan and the human angiotensin II AT1 receptor. Br J Pharmacol2007; 151: 952-962.
16.
Seifert R., Wenzel-Seifert K.Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn Schmiedebergs Arch Pharmacol2002; 366: 381-416.
17.
Miura S., Kiya Y., Kanazawa T., et al. Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state. Mol Endocrinol2008; 22: 139-146.
18.
Miura S., Fujino M., Hanzawa H., et al. Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor. J Biol Chem2006; 281: 19288-19295.
19.
Morisset S. , Rouleau A., Ligneau X., et al. High constitutive activity of native H3 receptors regulates histamine neurons in brain. Nature2000; 408: 860-864.
20.
Kijima K., Matsubara H., Murasawa S., et al. Mechanical stretch induces enhanced expression of angiotensin II receptor subtypes in neonatal rat cardiac myocytes. Circ Res1996; 79: 887-897.
21.
Yasuda N., Miura S., Akazawa H., et al. Conformational switch of angiotensin II type 1 receptor underlying mechanical stress-induced activation. EMBO Rep2008; 9: 179-186.
22.
Zou Y., Akazawa H., Qin Y., et al. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol2004; 6: 499-506.
23.
Vasan RS, Levy D.The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview. Arch Intern Med1996 ; 156: 1789-1796.
24.
Pitt B., Poole-Wilson PA, Segal R., et al. Randomised trial of losartan versus captopril on mortality in patients with symptomatic heart failure: the losartan heart failure survival study - ELITE II. Lancet2000; 355: 15822-15827.
25.
Pfeffer MA, Swedberg K., Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet2003; 362: 759-766.
26.
Hernandez-Presa M., Bustos C., Ortego M., et al. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kB activation, monocyte chemoattractant protein-1 expression and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation1997; 95: 1532-1541.
27.
Proudfoot JM , Croft KD, Puddey IB, and Beilin LJAngiotensin II type 1 receptor antagonists inhibit basal as well as low-density lipoprotein and platelet-activating factor-stimulated human monocyte chemoattractant protein-1. J Pharmacol Exp Ther2003; 305: 846-853.
28.
Clasen R., Schupp M., Foryst-Ludwig A., et al. PPARgammaactivating angiotensin type-1 receptor blockers induce adiponectin. Hypertension2005; 46: 137-143.
29.
Marshall TG , Lee RE, and Marshall FECommon angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b. Theor Biol Med Model2006; 3: 1.
30.
Scheen AJPrevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system. Drugs2004; 64: 2537-2565.
31.
Furuhashi M. , Ura N., Higashiura K., et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension . Hypertension2003; 42: 76-81.
32.
Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation2004; 110: 3687-3692.
33.
Schupp M., Janke J., Clasen R., Unger T., and Kintscher U.Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation2004; 109: 2054-2057.
34.
Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension2004; 43: 993-1002.
35.
Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med2001; 345: 851-860.
36.
Parving HH, Lehnert H., Bröchner-Mortensen J., et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med2001; 345: 870-878.
37.
Brenner BM, Cooper ME, de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med2001; 345: 861-869.
38.
Iwanaga T., Sato M., Maeda T., Ogihara T., and Tamai I.Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J Pharmacol Exp Ther2007; 320: 211-217.
39.
Picca M., Agozzino F., and Pelosi G.Effects of losartan and valsartan on left ventricular hypertrophy and function in essential hypertension. Adv Ther2004; 21: 76-86.
40.
Pool JL, Guthrie RM, Littlejohn TW 3rd, et al. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens1998; 11: 462-470.
41.
Krämer C. , Sunkomat J., Witte J., et al. Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. Circ Res2002; 90: 770-776.
42.
Pantev E., Stenman E., Wackenfors A., Edvinsson L., and Malmsjo M.Comparison of the antagonistic effects of different angiotensin II receptor blockers in human coronary arteries. Eur J Heart Fail2002; 4: 699-705.
43.
Iwata A., Miura S., Imaizumi S., et al. Do valsartan and losartan have the same effects in the treatment of coronary artery disease?Circ J2007; 71: 32-38.
44.
Sugihara M. , Miura S., Takamiya Y., et al. Safety and efficacy of antihypertensive therapy with add-on angiotensin II type 1 receptor blocker after successful coronary stent implantation. Hypertens Res2009; 32: 625-630.
45.
Yamada S., Ano N., Toda K., et al. Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro. Hypertens Res2008; 31: 601-606.
46.
Nunez A., Gomez J., Zalba LR, et al. Losartan inhibits in vitro platelet activation: comparison with candesartan and valsartan. J Renin Angiotensin Aldosterone Syst2000; 1: 175-179.
47.
Nakayama S. , Watada H., Mita T., et al. Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension. Hypertens Res2008; 31: 7-13.
48.
Sasaki T., Noda Y., Yasuoka Y., et al. Comparison of the effects of telmisartan and olmesartan on home blood pressure, glucose, and lipid profiles in patients with hypertension, chronic heart failure, and metabolic syndrome. Hypertens Res2008; 31: 921-929.
